To conclude, we demonstrated that CD56neg CD16+ NK cells represent a distinct NK cell subset that can recover CD56 expression in vitro and display NK cell functions, which could be leveraged to counteract the adverse clinical outcome of AML patients with CD56neg CD16+ NK cells expansion. This evidence concerns the gene NCAM1 and acute myeloid leukemia.